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Background: ER-positive (ER+ ) breast cancer includes all of the intrinsic molecular subtypes, although the luminal A
and B subtypes predominate. In this study, we evaluated the ability of six clinically relevant genomic signatures to
predict relapse in patients with ER+ tumors treated with adjuvant tamoxifen only.
Methods: Four microarray datasets were combined and research-based versions of PAM50 intrinsic subtyping and
risk of relapse (PAM50-ROR) score, 21-gene recurrence score (OncotypeDX), Mammaprint, Rotterdam 76 gene, index
of sensitivity to endocrine therapy (SET) and an estrogen-induced gene set were evaluated. Distant relapse-free survival
(DRFS) was estimated by Kaplan–Meier and log-rank tests, and multivariable analyses were done using Cox regression
analysis. Harrell’s C-index was also used to estimate performance.
Results: All signatures were prognostic in patients with ER+ node-negative tumors, whereas most were prognostic in
ER+ node-positive disease. Among the signatures evaluated, PAM50-ROR, OncotypeDX, Mammaprint and SET were
consistently found to be independent predictors of relapse. A combination of all signatures significantly increased the
performance prediction. Importantly, low-risk tumors (>90% DRFS at 8.5 years) were identified by the majority of
signatures only within node-negative disease, and these tumors were mostly luminal A (78%–100%).
Conclusions: Most established genomic signatures were successful in outcome predictions in ER+ breast cancer and
provided statistically independent information. From a clinical perspective, multiple signatures combined together most
accurately predicted outcome, but a common finding was that each signature identified a subset of luminal A patients
with node-negative disease who might be considered suitable candidates for adjuvant endocrine therapy alone.
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introduction
Gene expression-based assays have been developed that can
successfully predict outcomes in early-stage ER-positive (ER+)
breast cancer beyond standard clinicopathological variables [1–
5]. OncotypeDX recurrence score (GHI)2 and Mammaprint®
(NKI70)3 are clinically available and currently being evaluated
in two large prospective clinical trials (TAILORx and
MINDACT) [6, 7]. Since then, other prognostic predictors
such as the Rotterdam 76-gene signature (ROT76) [8, 9] and
the risk of relapse (ROR) score based on the PAM50 subtype
assay [10] have been developed using two different node-
negative and adjuvant treatment-naive populations.
Previous studies have also shown that many of these
expression signatures are concordant for predicting outcomes
[11, 12]. However, it is currently unknown if these findings are
still valid in a more contemporary ER+ population treated with
adjuvant endocrine therapy only [13]. Moreover, recent
signatures specifically designed to track hormonal
responsiveness, such as the estrogen-induced gene set (IE-IIE)
[14] and the genomic index of sensitivity to endocrine therapy
(SET) [15], can also predict survival in early-stage ER+ disease.
Thus, estrogen-regulated gene signatures could be tracking ER
+ tumors with high endocrine sensitivity.
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From a clinical perspective, genomic assays are helping to
identify patients with early-stage ER+ breast cancers who do
not need chemotherapy and are effectively treated with
adjuvant endocrine agents alone. Alternatively, they could
identify groups of patients with ER+ tumors who are more
likely to be biologically homogenous and/or who might benefit
from specific treatment strategies. In this report, we evaluated
the relapse prediction abilities of six independent genomic
signatures using a cohort of ER-positive breast cancer patients
treated with adjuvant tamoxifen only.
methods
patients and samples
Four different publicly available microarray datasets were combined
together to create a single large set of 594 ER+ patients, all of whom
received appropriate local therapy and adjuvant tamoxifen only (see
supplemental Figure S1, available at Annals of Oncology online). Thousand
fifty-three Affymetrix U133A CEL files from various publicly available
microarray datasets (GSE17705 [MDACC298] [15], GSE6532 [LOI327] [16,
17], GSE12093 [ZHANG136] [18], GSE1456 [PAWITAN159] [19] and
MDACC133 [20]) were processed using MAS 5.0 (R/Bioconductor) to
generate probe-level intensities with a median array intensity of 600, and
each expression value was log2 transformed. To batch correct the gene
expression data [21, 22], the probeset medians in each individual dataset
were adjusted to the MDACC133 reference set accounting for differences in
the proportion of clinical ER+ /− samples; after batch correction, all ER−
tumors were removed, as were all ER+ tumors not treated with tamoxifen-
only, thus leaving 594 tumors per microarrays.
genomic predictors
The following gene expression signatures were evaluated using the
combined microarray dataset: GHI [2], NKI70 [3], ROT76 [8], IE-IIE [14],
SET [15] and PAM50 [10] (supplemental Table S1, available at Annals of
Oncology online). Each signature was evaluated as a continuous variable
and as group categories according to the published cut-offs [2, 3, 8, 10, 14,
15]. Briefly, the intrinsic subtypes, the risk of relapse based on subtype
(PAM50-RORS), the ROR based on subtype and proliferation (PAM50-
RORP) and the proliferation index (PAM50-PROLIF) were identified using
the PAM50 subtype assay [10]. The PAM50-PROLIF index is the mean
expression of 11 PAM50 proliferation-related genes of the PAM50 assay
[23]. GHI and NKI70 were evaluated as previously described [12]. For the
IE-IIE signature, we calculated the Spearman correlation to the two
training centroids (IE and IIE) as described by Oh et al. [14]; samples with
a correlation ratio to the IE centroid/IIE centroid >1.0 were assigned to the
IE group and the rest to the IIE group. Finally, for the ROT76 and SET
signatures, all Affymetrix U133A probes were evaluated as described in
both publications, respectively [8, 15]. The list of gene and/or probes, the
scores and the group categories for each signature can be obtained from
supplemental data, available at Annals of Oncology online.
To further explore the PAM50, results were obtained from combining
the microarray dataset with a qunatitative RT-PCR (qRT-PCR) dataset of
786 ER+ breast cancer patients treated with adjuvant tamoxifen only from
Nielsen et al. [23] (Nielsen series).
statistical analysis
Distant relapse-free survival (DRFS) estimates were from the Kaplan–Meier
curves and tests of differences by the log-rank test. The DRFS follow-up
time was censored at 8.5 years since it was the longest follow-up time in
the PAWI159 [19] dataset. Univariate and multivariable analyses (MVA)
were calculated using a Cox proportional regression model.
MVA prognostic models including all the signatures as independent
continuous variables were built and assessed using a Cox model with the
penalized least absolute shrinkage and selection operator (LASSO) method
approach [24]. In each case, a training set (2/3 of the dataset) was
randomly used to build a model, which was then applied to the testing set
(i.e. the remaining 1/3). We repeated this procedure 200 times as
previously carried out [5]. In each testing set, the prognostic performance
of each model and each individual signature was estimated by calculating
the concordance index (C-index) [25]. All statistical computations were
carried out in R v.2.8.1 (http://cran.r-project.org).
results
clinicopathological characteristics of the combined
microarray and qRT-PCR PAM50 dataset
We created a large dataset of 1380 ER-positive breast cancer
patients treated with adjuvant tamoxifen only using publicly
available microarray data (n = 594) and PAM50 qRT-PCR data
only (n = 786) from the Nielsen series [4, 15–19]. Six hundred
and ten and 699 patients were identified as having node-
negative and node-positive disease, respectively (Table 1). As
expected, luminal subtypes predominated (n = 1171, 84.9%).
Non-luminal subtypes (HER2-enriched and basal-like)
represented 9.1% (n = 125) of the patients. The normal breast-
like samples were not further considered as these specimens
are predominantly composed of normal breast tissue, which
precludes the correct assignment to a tumor subtype for
meaningful outcome predictions [1, 10].
The PAM50 intrinsic subtypes were prognostic for DRFS
within node-negative and node-positive patients (Figure 1A
and B). In node-negative disease, luminal A tumors showed a
better outcome than luminal B [hazard ratio (HR) = 0.313, P <
0.0001], HER2-enriched (HR = 0.256, P < 0.001) and basal-like
(HR = 0.168, P < 0.001) subtypes. However, no statistical
significant differences in DRFS were observed among the poor
prognostic luminal B, HER2-enriched and basal-like subtypes.
In node-positive disease, the PAM50 subtypes were also
prognostic; of note, DRFS of both luminal subtypes was
significantly lower compared with their counterparts in node-
negative disease (luminal A, HR = 3.29 and luminal B, HR =
2.26, P < 0.0001 for both comparisons). Regardless of nodal
status, both luminal subtypes had continued risk of relapse
after 5 years; even the lowest risk node-negative luminal A
subtype had 5-year DRFS of 96% that dropped to 91% by 8.5
years. A tendency for worse outcomes was also observed in
node-positive HER2-enriched tumors compared with node-
negative HER2-enriched tumors (HR = 1.91, P = 0.099).
genomic relationships and biological significance
For comparisons across different predictors, the combined
dataset was confined to the 594 samples/tumor represented by
Affymetrix microarray data. We first compared the gene
overlap between any two signatures and found that ≤25% of
the genes were shared between signatures (supplemental
Table S2, available at Annals of Oncology online), except for 9
and 11 genes of the GHI signature (n = 21) that were present
Annals of Oncology original articles
Volume 23 | No. 11 | November 2012 doi:10.1093/annonc/mds080 | 
in the IE-IIE and PAM50, respectively, and 15 genes of the IE-
IIE signature that were present in PAM50. In spite of relatively
little gene overlap, all predictors were significantly correlated
(Pearson correlation range 0.36–0.79; P < 0.0001 for each
comparison), with PAM50-RORS, IE-IIE and GHI showing the
highest correlation between them (>0.72, P < 0.0001, Pearson
correlation; supplemental Table S2, available at Annals of
Oncology online).
The observed correlations suggested that most predictors are
tracking tumors with similar biology. To further explore this
hypothesis, we evaluated the scores of each signature as a
continuous variable and as group categories across the four
major intrinsic subtypes (as defined by the PAM50 assay [10]).
As expected, each predictor discriminated luminal A tumors
from the luminal B subtype and from the rest of the subtypes
[P < 0.0001, Student’s t-test (supplemental Figure S3 and
Table S3, available at Annals of Oncology online)]. The high
hormonal sensitivity groups (SET-high and IE-like) and low
risk of recurrence groups (PAM50-RORS-low, PAM50-RORP-
low, GHI-low, ROT76-good and NKI-good) were largely
composed of luminal A tumors (>71%–100%).
survival analyses within node-negative
and node-positive disease
Univariate DRFS analyses revealed that each signature,
evaluated as a continuous variable or as group categories, was
highly prognostic in patients with node-negative disease
(supplemental Figure S4 and Table S4, available at Annals of
Oncology online). As expected, Kaplan–Meier survival analyses
showed highly significant differences in DRFS across the
groups predicted to have good or intermediate or poor
prognosis (PAM50-RORS, PAM50-RORP, GHI, ROT76 and
NKI70) or the groups predicted to have high or intermediate
versus low expression of ER-regulated genes (SET and IE-IIE).
Importantly, all predictors identified groups of node-negative
Table 1. Clinicopathological characteristics of the combined microarray and qRT-PCR patient dataset
Symmans
et al. [15]







Dataset MDACC298 LOI327 ZHANG136 PAWI159 NIELSEN
GSE series GSE17705 — GSE6532 — GSE12093 — GSE1456 — — — — —
Patientsa 298 100% 73 22% 136 100% 87 55% 786 100% 1380 —
Node-negativeb 175 61% 20 29% 136 100% 57 69% 222 30% 610 47%
Node-positiveb 112 39% 50 71% 0 0% 26 31% 511 70% 699 53%
PAM50 subtypesc
Luminal A 132 44% 34 47% 66 49% 40 46% 372 47% 644 47%
Luminal B 100 34% 19 26% 48 35% 31 36% 329 42% 527 38%
HER2-enriched 16 5% 10 14% 5 4% 5 6% 64 8% 100 7%
Basal-like 8 3% 4 5% 4 3% 4 5% 5 1% 25 2%
Normal-like 42 14% 6 8% 13 10% 7 8% 16 2% 84 6%
aOnly patients with ER+ disease treated with tamoxifen-only were selected from these datasets. In GSE6532, 103 samples have been removed since they
overlap with GSE17705.
bGSE17705, GSE1456, GSE6532 and Nielsen et al. [23] have 11, 4, 3 and 53 patients without node status, respectively (total n = 71).
cSubtype data in Nielsen et al. were obtained by the qRT-PCR PAM50 assay.
qRT-PCR, quantitative RT-PCR.
Figure 1. Kaplan–Meier DRFS analysis of intrinsic subtype as determined by PAM50 gene expression measurement (quantitative reverse transcription–
PCR and microarray-based) from women with (A) node-negative and (B) node-positive invasive breast carcinoma, treated with adjuvant tamoxifen only.
The number of patients and the estimated DRFS at 8.5 years in each group are shown beside each curve’s description. DRFS, distant relapse-free survival.
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patients with 93.7%–97.9% and 88.4%–96.2% DRFS at 5.0 and
8.5 years, respectively, although the number of patients in each
group differed (Table 2); when limited to the combined
microarray dataset and across the predictors with three risk
categories (GHI, SET, PAM50-RORS and PAM50-RORP), the
PAM50-RORS identified the largest number of low-risk
patients (n = 140, 41%), followed by PAM50-RORP (n = 82,
24%), GHI (n = 47, 14%) and SET (n = 27%). Inclusion of the
786 ER+ patient qRT-PCR PAM50 Nielsen series data
confirmed that both PAM50-RORP and PAM50-RORS
identify 21%–36% of all node-negative patients (n = 551) as
low risk [or alternatively they identify 41%–70% of all node-
negative luminal A tumors (n = 280) as low risk], and the
PAM50-RORP-low and PAM50-RORS-low groups showed a
DRFS at 8.5 years of 96.09% and 91.21%, respectively (Table 2
and supplemental Figure S5, available at Annals of Oncology
online).
In node-positive disease, univariate DRFS analyses revealed
that most signatures were barely significant when evaluated as
continuous variables (supplemental Figure S6 and Table S4,
available at Annals of Oncology online). When evaluated as
group categories, low risk of relapse or high expression of ER-
regulated gene groups showed either no statistical significance
or borderline significance in terms of DRFS compared with the
predicted poor prognostic or low expressers of ER-regulated
gene groups. More importantly, no predictor identified a clear
node-positive group of patients treated with tamoxifen alone
with a DRFS at 8.5 years >90%. Although these results could
be related to the sample size, data for PAM50-RORS and
PAM50-RORP in node-positive disease confirmed this finding
when the qRT-PCR PAM50 Nielsen series was included for a
total of 676 patients (supplemental Figure S5, available at
Annals of Oncology online). Finally, similar to node-negative
disease, the predicted low-risk outcome groups in node-
positive disease were predominantly comprised of luminal A
tumors (71%–100%; Table 2).
prognostic prediction performance
C-index values were calculated to estimate the performance of
each genomic signature for predicting outcome (Figure 2). The
C-index is a measure of the probability of concordance
between the predicted and the observed survival, ranging from
0.5 (random) to 1 (perfect). Although no clear cut-off value
has been defined, values >0.70 are indicative of good prediction
accuracy [25]. In node-negative disease, the vast majority of
signatures showed similar predictive abilities (mean C-index
range of 0.70–0.73), except PAM50-PROLIF index (mean C-
index of 0.69) and NKI70 (mean C-index of 0.64). Conversely,
in node-positive disease, all predictors carried out worse than
in node-negative (mean C-index range of 0.56–0.63).
Despite comparable prognostic performance of these
signatures and high correlation values among them, we
observed that these signatures generally retained their
prognostic significance independent of each other when testing
two signatures at a time in multivariate analyses (Table 3).
Thus, we sought to determine if we could improve prognostic
performance by integrating information from all signatures
into a single model; we determined that the combined model
was better at predicting outcome than individual signatures in
node-negative disease (Figure 2A) but failed in node-positive
disease (Figure 2B). However, the absolute increase in
performance of the combined model within node-negative
disease was modest (range 0.02–0.11).
prognostic predictions within the intrinsic subtypes
We explored the predictive ability of each signature within the
predominant luminal A and B subtypes. In node-negative
luminal A disease (n = 185), ROT76 and SET (Figure 3A) were
found to be prognostic in univariate analyses, and patients
with the low-risk group showed a DRFS at 8.5 years of 94%–
96% (supplemental Table S5, available at Annals of Oncology
online). When limited to the microarray dataset, the PAM50-
Table 2. Low-risk group comparison among signatures
Node-negative Node-positive
Low-risk group Low-risk group
N % of luminal A DRFS at 8.5 years N % of luminal A DRFS at 8.5 years
RORP (PAM50) 82 (24%) 100% 94% 38 (22%) 100% 80%
RORS (PAM50) 140 (41%) 100% 90% 63 (37%) 100% 74%
PROLIFa (PAM50) 72 (22%) 100% 93% 33 (19%) 100% 82%
GHI 47 (14%) 94% 95% 14 (8%) 93% 81%
ROT76b 164 (48%) 85% 92% 81 (47%) 77% 76%
IE-IIEb 235 (69%) 72% 88% 100 (58%) 71% 69%
NKI70b 136 (40%) 78% 91% 53 (31%) 79% 76%
SET 26 (8%) 81% 96% 21 (12%) 91% 89%
RORP (PAM50)c 116 (21%) 100% 96% 116 (17%) 100% 84%
RORS (PAM50)c 197 (36%) 100% 91% 197 (29%) 100% 79%
PROLIF (PAM50)c 142 (26%) 99% 95% 166 (24%) 99% 80%
aSince proliferation (PROLIF) index does not have previously defined cut-offs, patients in the low-risk group are the ones with the lowest quartile expression.
bROT76, IE-IIE and NKI70 signatures have two risk categories.
cqRT–PCR PAM50 data from the Nielsen series have been included. N, number of patients in the low-risk group and the percentage from the total number
of patients based on node status.
DRFS, distant relapse-free survival.
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RORS and PAM50-RORP were trending toward significance
(supplemental Table S5, available at Annals of Oncology online)
and both were significant when the Nielsen series was included
for a total of 280 luminal A patients (supplemental Table S5,
available at Annals of Oncology online and PAM50-RORP in
Figure 3B).
In node-positive luminal A disease (n = 81) on the
microarray dataset, GHI, NKI70 and IE-IIE were prognostic
when evaluated as a continuous variable, and the combined
low and intermediate risk GHI groups identified a group of
significantly low-risk node-positive luminal A tumors (n = 30,
37%) with an outstanding DRFS at 8.5 years (96%, P < 0.01;
Figure 3C). When we included the qRT-PCR PAM50 Nielsen
series dataset (n = 326), PAM50-RORS and PAM50-RORP
were found prognostic as a continuous variable and as group
categories, with the low-risk PAM50-RORP group achieving a
DRFS at 8.5 years of 84.02% (P < 0.01; Figure 3D).
Within the luminal B subtype (n = 120), the vast majority of
signatures were found to be prognostic when evaluated as a
continuous variable in node-negative disease (supplemental
Table S6, available at Annals of Oncology online); however, no
statistically significant group of patients with >90% DRFS at
8.5 years was identified by any of the predictors (supplemental
Table S6, available at Annals of Oncology online); similar
findings were obtained when we included the qRT-PCR
PAM50 Nielsen series dataset. Finally, no significant
prognostic ability was found within node-positive luminal B
tumors, with (n = 285) or without (n = 70) the Nielsen series,
respectively (supplemental Table S6, available at Annals of
Oncology online).
discussion
Our data indicates that (i) clinically used signatures and ER-
regulated gene signatures are tracking tumors with similar
underlying biology (luminal A versus not) and show significant
agreement in outcome predictions; (ii) the performance of
these signatures is most relevant in node-negative disease; and
(iii) some single genomic signatures can perform nearly as well
as a combination of two or more signatures, although a
combination of multiple signatures was statistically the best.
Importantly, this is the first report to show that groups of
patients with >95% DRFS at 8.5 years might only be
consistently identified within node-negative and luminal A
disease. Alternatively, for patients with luminal B cancer
treated only with tamoxifen, additional therapies should be
offered, which, as of today, would suggest chemotherapy.
These results also demonstrate that most of the signatures
evaluated in this study can provide similar outcome
predictions, although significant differences across predictors
Figure 2. Comparison of prognostic classifiers and single genes in (A) node-negative and (B) node-positive subjects. The C-index is used to compare
accuracy of the prognostic classifiers and single genes. Signatures have been ranked ordered from highest to lowest mean C-index. In node-negative disease,
the C-index of the combined model was superior to the C-index of each individual signature in at least 75% of the 200 total estimations.
Table 3. Multivariate Cox proportional hazards analyses of distant relapse-free survival among predictorsa
Adjusted on the following predictor
PAM50-RORP PAM50-RORS PAM50-PROLIF GHI ROT76 IE-IIE NKI70 SET
Predictor χ2 statistic
and P value
PAM50-RORP 10.6; 0.005 7.2; 0.027 11.5; 0.003 9.6; 0.008 10.45; 0.005 16.2; <0.001 17.4; <0.001
PAM50-RORS 0.0; 0.990 1.0; 0.617 5.4; 0.067 2.9; 0.240 3.1; 0.220 7.1; 0.029 9.2; 0.012
PAM50-PROLIF 0.2; 0.890 4.6; 0.099 7.6; 0.023 4.6; 0.100 5.8; 0.056 10.7; 0.005 13; 0.002
GHI 9.1; 0.010 13.6; 0.001 12.2; 0.002 13.5; 0.001 13.4; 0.001 14.4; <0.001 20.0; <0.001
ROT76 4.3; 0.031 8.29; 0.004 6.4; 0.012 10.7; 0.001 10.4; 0.001 13.0; <0.001 11.0; 0.0013
IE-IIE 3.2; 0.072 6.4; 0.011 5.5; 0.019 8.6; 0.003 8.4; 0.004 9.2; 0.002 12.0; 0.001
NKI70 5.7; 0.022 7.3; 0.007 7.24; 0.013 9.2; 0.002 7.8; 0.005 6.1; 0.014 14.0; <0.001
SET 6.6; 0.042 9.0; 0.011 8.7; 0.012 13.6; 0.001 9.7; 0.008 8.5; 0.015 13.6; 0.001
aEach square denotes the change in the likelihood ratio statistic (χ2) of the signature in each row and its P value when conditioned on a signature in the
column.
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are present. This result is harmonious with our previous
observation of concordance between intrinsic subtypes, NKI70
and GHI in a cohort of heterogeneously treated ER+ and ER−
breast cancer patients [12]. Importantly, here, we show that
these and other signatures are tracking ER+ tumors with a
similar biology. Indeed, the vast majority of ER+ tumors
identified here as having either basal-like, HER2-enriched or
luminal B subtypes were correctly classified by the other
signatures as having a poor prognosis. On the other hand,
luminal A tumors were mostly identified as having good
outcome and showing high expression of ER-regulated
signatures. Interestingly, a recent neoadjuvant aromatase
inhibitor clinical trial reported that the luminal A subtype
benefits the most from endocrine therapy [26].
The performance of each predictor in node-positive disease
was significantly worse when compared with node-negative
disease, and almost no group of patients with node positivity
had a DRFS >90% at 8.5 years by any predictor; the only
exceptions being GHI within luminal A disease. In two
previously published node-positive ER+ cohorts receiving
adjuvant endocrine treatment only (TransATAC and SWOG-
8814), the 9-year DRFS and 10-year disease-free survival
estimates were 83% and 60% for the low-risk groups of the
GHI, respectively [27, 28]. A plausible biological explanation is
that in advanced luminal A primaries, a small percentage of
cells within the bulk of the tumor have already metastasized
and/or acquired endocrine resistance. Indeed, the presence of
these subclones is supported by data from a neoadjuvant
endocrine trial [29]. However, within node-positive luminal A
tumors, some patients with the low and intermediate risk score
of GHI had a DRFS at 8.5 years >90%. Hence, future studies
are warranted to determine if these or other predictors can
identify, within the luminal A subtype, a group of node-
positive patients whose survival with endocrine therapy could
preclude the administration of adjuvant chemotherapy. The
MINDACT [6] trial, which has completed accrual, and the
RxPONDER trial (NCT01272037) will address this issue,
particularly for patients with one to three positive lymph
nodes.
Multivariate analyses including two predictors at a time
revealed that, in most cases, many of these correlated
predictors, in particular the PAM50-RORP, GHI, NKI70 and
SET, remained statistically independent of each other (Table 3).
This finding suggests that these predictors are not the same. In
fact, at the individual level, the risk group assignment
concordance among these predictors was found to be 36% for
PAM50-RORP versus GHI, 54% for PAM50-RORP (low/med
versus high) versus NKI70 and 74% for GHI (low/intermediate
versus high) versus NKI70. Cohen’s kappa coefficients between
risk group assignments were also indicative of slight to fair
agreement (range 0.11–0.42) [30, 31]. The clinical relevance of
this finding is currently unknown. However, a plausible
explanation is that these signatures might be tracking different
poor outcome luminal/ER+ subtypes; support for this
Figure 3. Kaplan–Meier DRFS analysis of selected gene signatures within luminal A disease treated with adjuvant tamoxifen only. (A) SET index within
node-negative luminal A tumors; (B) PAM50-RORP within node-negative luminal A tumors (Nielsen series included); (C) GHI within node-positive
luminal A tumors; (D) PAM50-RORP within node-positive luminal A tumors (Nielsen series included). The complete survival analyses can be found in
supplemental Tables S5 and S6, available at Annals of Oncology online. DRFS, distant relapse-free survival.
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heterogeneity comes from Parker et al. [10], where five
statistically significant groups of luminal tumors were
identified. Nonetheless, when we built a model here using all
predictors, we only observed modest improvements in
performance. This finding suggests that gene expression
profiling may be reaching its maximum prognostic power.
There are several important caveats to our analyses that must
be recognized and always kept in mind when interpreting
‘across platform’ genomic studies. First, although we strove to
implement each predictor as published, signatures developed
on platforms other than the Affymetrix U133A were
suboptimally implemented. This is because when taking a
predictor from one technology and applying it to another
platform, different oligonucleotide probes/sequences are used
to represent each gene (and thus may not behave identically),
and each technology has unique normalization methods.
Second, changing platforms/technologies almost always causes
a loss of genes (see supplemental Table S1, available at Annals
of Oncology online), and this loss was significantly present for
PAM50 (6/50) and NKI70 (12/60), which likely explains the
observed lower performance of this predictor with respect to
others. Nonetheless, many of the across platform evaluated
predictors carried out well including the PAM50-ROR and
GHI; the survival outcomes of the GHI low-risk group within
node-negative disease was highly concordant to previous
publications [32] despite that the absolute survival rates are
highly dataset dependent. Finally, we could not compare the
prognostic ability of these signatures versus standard
clinicopathological variables since these variables were not
available from most microarray datasets. This highlights the
need for centralized collection of clinical and pathology data in
all genomic studies.
To conclude independently derived genomic predictors of
breast cancer recurrence perform similarly and are tracking
tumors with similar biology. However, most predictors were
statistically independent from the others and thus, these should
not be considered to be interchangeable assays. From a clinical
perspective, adding genomic signatures together provided
modest improvements in outcome prediction, but may not be
practical given cost.
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Explanatory factors of sexual function in sexual
minority women breast cancer survivors
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Background: The sexual function of sexual minority women (women with female partners) who are breast cancer
survivors is mostly unknown. Our objective is to identify explanatory factors of sexual function among sexual minority
women with breast cancer and compare them with a control sample of sexual minority women without cancer.
Patients and methods: Using a conceptual framework that has previously been applied to heterosexual breast
cancer survivors, we assessed the relationship of each explanatory factor to sexual function in sexual minority women.
Using generalized estimating equations, we identified explanatory factors of sexual function and identified differences by
case and control status.
Results: Self-perception of greater sexual attractiveness and worse urogenital menopausal symptoms explain 44% of
sexual function, after controlling for case and control status. Focusing only on partnered women, 45% of sexual
function was explained by greater sexual attractiveness, postmenopausal status, and greater dyadic cohesion.
Conclusions: All of the relevant explanatory factors for sexual function among sexual minority survivors are modifiable
as has been suggested for heterosexual survivors. Sexual minority survivors differ from heterosexual survivors in that
health-related quality of life is less important as an explanatory factor. These findings can guide adaptation of
interventions for sexual minority survivors.
Key words: breast neoplasm, case–control study, female, homosexuality, sexual dysfunctions
introduction
Sexual dysfunction or difficulties remain a persistent concern of
breast cancer survivors (BCS) [1–3]. Sexual dysfunction is
common and distressing, affecting ∼50% of BCS [3–5].
Depending on the dimension of sexual function (desire, arousal,
orgasm, frequency of sexual activity) measured, the incidence of
sexual dysfunction varies from 15% to a high of 64% [4, 5].
Broeckel et al. [6] demonstrated worse sexual functioning in
long-term BCS compared with controls, including greater lack of
sexual interest, inability to relax and enjoy sex, difficulty
becoming aroused, and difficulty achieving orgasm. Study
findings are inconsistent when sexual frequency is used as the
measure of sexual functioning: Ganz et al. [4, 7] found no
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